Xolair Pediatric (Ages 6-11) BLA Extension Must Overcome "Relatively Modest" Efficacy

FDA briefing materials for Nov. 18 advisory committee meeting note reductions in asthma exacerbations but few clinically meaningful benefits on secondary efficacy measures.